SEC Filing Summary: Global Medical REIT Inc. (GMRE)
Business Context and Reporting Period
This Form 8-K Current Report, dated November 13, 2025, details a material capital raise by Global Medical REIT Inc. (GMRE). The filing reports the entry into an underwriting agreement for the issuance of new preferred stock and the corresponding amendment to the company's operating partnership agreement and articles of incorporation.
Key Financial Metrics and Transaction Details
- Security Issued: 8.00% Series B Cumulative Redeemable Preferred Stock.
- Shares Offered: 2,000,000 shares at a public offering price of $25.00 per share.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to an additional 300,000 shares.
- Total Potential Proceeds: Up to $57.5 million (based on 2.3 million shares at $25.00).
- Liquidation Preference: $25.00 per share.
- Expected Closing Date: November 20, 2025.
- Underwriters: Raymond James & Associates, Inc., BMO Capital Markets Corp., Stifel, Nicolaus & Company, Incorporated, and Robert W. Baird & Co. Incorporated.
Note: This filing does not provide current revenue, profit, cash flow, or debt metrics for the company. It focuses exclusively on the terms of the new equity issuance.
Material Changes and Corporate Actions
- Underwriting Agreement: Executed on November 13, 2025, for the sale of Series B Preferred Stock.
- Operating Partnership Amendment: The Agreement of Limited Partnership was amended to authorize the issuance of up to 2,300,000 Series B Preferred Units with economic terms mirroring the stock.
- Articles Supplementary: Filed on November 18, 2025, designating 2,300,000 shares of authorized preferred stock as Series B Preferred Stock.
- Distribution Restrictions: Upon issuance, the company's ability to make distributions on junior or parity stock is restricted if distributions on the Series B Preferred Stock are not declared.
Outlook, Risks, and Management Commentary
The filing indicates the company intends to contribute net proceeds from the stock sale to its Operating Partnership in exchange for Series B Preferred Units. The transaction is subject to customary closing conditions. The filing incorporates by reference the prospectus supplement for a full description of the stock's terms, powers, and privileges. No specific forward-looking guidance regarding future earnings or operational outlook is provided in this specific 8-K text.
Key Facts for Investor Verification
- Verify the final closing date and actual number of shares sold, including any exercise of the 300,000 share over-allotment option.
- Review the full prospectus supplement (Form S-3, Registration No. 333-276248) for detailed terms regarding redemption, voting rights, and dividend payment schedules.
- Confirm the use of proceeds and how the new preferred units impact the capital structure of the Operating Partnership.
- Assess the impact of the new 8.00% dividend obligation on the company's future cash flow and ability to pay common dividends.